T. Ibekwe, V. Kwaghe, Habib Zayad Garba, P. Ibekwe
{"title":"抗病毒药物在呼吸道合胞病毒、流感和COVID-19病例管理中的作用","authors":"T. Ibekwe, V. Kwaghe, Habib Zayad Garba, P. Ibekwe","doi":"10.35248/1948-5964.13.S16.002","DOIUrl":null,"url":null,"abstract":"Background: The Respiratory Syncytial, Influenza and the SARS-CoV-2 viruses have a lot in common and are intertwined as leading causes of respiratory infections (flu) and flu-like infections in humans. The morbidity, mortality and disease burden posed by these diseases across the globe is humongous. The epidemiology, pathophysiology, clinical presentations and sequalae of these respiratory illnesses are also very similar and could be safely described as a spectrum of a disease process ‘syncytial respiratory disease’. There is justification in simultaneously studying, investigating and researching on these diseases given their close similarities and thin differences. Methods: This is a review of the literature on Case-Management for RSV, Influenza, COVID-19 and the role of Antiviral drugs. A comprehensive search of MEDLINE (from Jan 2019 to January 2021), EMBASE (from Jan 2019 to January 2021), Publics Ovidius Naso (Ovoid), Database of Abstracts of Reviews of Effects and the Cochrane Central Register of Controlled Trials in Issue 1 of 12, January 2021 of the Cochrane Library was performed. Short-listing of titles and abstracts on the basis of their relevance to the review and subsequent data extraction were undertaken independently by two out of the four authors (TSI and PUI). Differences were resolved by mutual consensus. Results: The Respirtory Syncitial Virus (RSV), Influenza and SARS-CoV2 (COVID-19) virus were all examined in detail. The similarities and differences were x-rayed, including the mechanism of transmission, pathophysiology and pathogenesis of each. The methods of treatment especially susceptibility on antiviral agents were discussed. Conclusion: The similarity indices between RSV, Influenza and SARS-CoV2 are strong. Non-pharmaceutical and pharmaceutical measures are required for holistic cure and total eradication of these diseases. Effective and efficient antiviral agent(s) are needed for active management of these groups of viruses and science is challenged to this effect.","PeriodicalId":15020,"journal":{"name":"Journal of Antivirals & Antiretrovirals","volume":"11 1","pages":"1-5"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Role of Antiviral Drugs in the Case-Management of Respiratory Syncytial Virus, Influenza and COVID-19\",\"authors\":\"T. Ibekwe, V. Kwaghe, Habib Zayad Garba, P. Ibekwe\",\"doi\":\"10.35248/1948-5964.13.S16.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: The Respiratory Syncytial, Influenza and the SARS-CoV-2 viruses have a lot in common and are intertwined as leading causes of respiratory infections (flu) and flu-like infections in humans. The morbidity, mortality and disease burden posed by these diseases across the globe is humongous. The epidemiology, pathophysiology, clinical presentations and sequalae of these respiratory illnesses are also very similar and could be safely described as a spectrum of a disease process ‘syncytial respiratory disease’. There is justification in simultaneously studying, investigating and researching on these diseases given their close similarities and thin differences. Methods: This is a review of the literature on Case-Management for RSV, Influenza, COVID-19 and the role of Antiviral drugs. A comprehensive search of MEDLINE (from Jan 2019 to January 2021), EMBASE (from Jan 2019 to January 2021), Publics Ovidius Naso (Ovoid), Database of Abstracts of Reviews of Effects and the Cochrane Central Register of Controlled Trials in Issue 1 of 12, January 2021 of the Cochrane Library was performed. Short-listing of titles and abstracts on the basis of their relevance to the review and subsequent data extraction were undertaken independently by two out of the four authors (TSI and PUI). Differences were resolved by mutual consensus. Results: The Respirtory Syncitial Virus (RSV), Influenza and SARS-CoV2 (COVID-19) virus were all examined in detail. The similarities and differences were x-rayed, including the mechanism of transmission, pathophysiology and pathogenesis of each. The methods of treatment especially susceptibility on antiviral agents were discussed. Conclusion: The similarity indices between RSV, Influenza and SARS-CoV2 are strong. Non-pharmaceutical and pharmaceutical measures are required for holistic cure and total eradication of these diseases. Effective and efficient antiviral agent(s) are needed for active management of these groups of viruses and science is challenged to this effect.\",\"PeriodicalId\":15020,\"journal\":{\"name\":\"Journal of Antivirals & Antiretrovirals\",\"volume\":\"11 1\",\"pages\":\"1-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Antivirals & Antiretrovirals\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35248/1948-5964.13.S16.002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Antivirals & Antiretrovirals","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/1948-5964.13.S16.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:呼吸道合胞病毒、流感病毒和SARS-CoV-2病毒有很多共同之处,它们是人类呼吸道感染(流感)和流感样感染的主要原因。这些疾病在全球造成的发病率、死亡率和疾病负担是巨大的。这些呼吸系统疾病的流行病学、病理生理学、临床表现和后遗症也非常相似,可以安全地描述为疾病过程的频谱“合胞性呼吸系统疾病”。鉴于这些疾病的相似之处和细微的差异,同时研究、调查和研究这些疾病是有道理的。方法:对RSV、流感、COVID-19病例管理及抗病毒药物作用的文献进行综述。综合检索MEDLINE(2019年1月至2021年1月)、EMBASE(2019年1月至2021年1月)、Publics Ovidius Naso (Ovoid)、Database of Reviews of Effects Abstracts and Cochrane Central Register of Controlled Trials (Cochrane中央对照试验注册库),检索日期为Cochrane图书馆2021年1月12期第1期。四名作者中的两名(TSI和PUI)独立进行了与综述相关的标题和摘要的简短列表和随后的数据提取。分歧通过相互协商一致解决了。结果:对呼吸道合胞病毒(RSV)、流感病毒和SARS-CoV2 (COVID-19)病毒进行了详细检测。对其异同点进行x线观察,包括传播机制、病理生理及病机。讨论了治疗方法,特别是对抗病毒药物的敏感性。结论:RSV病毒、流感病毒和SARS-CoV2病毒具有较强的相似性。为了全面治疗和彻底根除这些疾病,需要采取非药物和药物措施。需要有效和高效的抗病毒药物来主动管理这些病毒群,科学在这方面受到挑战。
The Role of Antiviral Drugs in the Case-Management of Respiratory Syncytial Virus, Influenza and COVID-19
Background: The Respiratory Syncytial, Influenza and the SARS-CoV-2 viruses have a lot in common and are intertwined as leading causes of respiratory infections (flu) and flu-like infections in humans. The morbidity, mortality and disease burden posed by these diseases across the globe is humongous. The epidemiology, pathophysiology, clinical presentations and sequalae of these respiratory illnesses are also very similar and could be safely described as a spectrum of a disease process ‘syncytial respiratory disease’. There is justification in simultaneously studying, investigating and researching on these diseases given their close similarities and thin differences. Methods: This is a review of the literature on Case-Management for RSV, Influenza, COVID-19 and the role of Antiviral drugs. A comprehensive search of MEDLINE (from Jan 2019 to January 2021), EMBASE (from Jan 2019 to January 2021), Publics Ovidius Naso (Ovoid), Database of Abstracts of Reviews of Effects and the Cochrane Central Register of Controlled Trials in Issue 1 of 12, January 2021 of the Cochrane Library was performed. Short-listing of titles and abstracts on the basis of their relevance to the review and subsequent data extraction were undertaken independently by two out of the four authors (TSI and PUI). Differences were resolved by mutual consensus. Results: The Respirtory Syncitial Virus (RSV), Influenza and SARS-CoV2 (COVID-19) virus were all examined in detail. The similarities and differences were x-rayed, including the mechanism of transmission, pathophysiology and pathogenesis of each. The methods of treatment especially susceptibility on antiviral agents were discussed. Conclusion: The similarity indices between RSV, Influenza and SARS-CoV2 are strong. Non-pharmaceutical and pharmaceutical measures are required for holistic cure and total eradication of these diseases. Effective and efficient antiviral agent(s) are needed for active management of these groups of viruses and science is challenged to this effect.